Company Overview and News
Kelington Group Bhd (Oct 3, RM1.19) Initiate coverage with buy and a target price (TP) of RM1.60: Kelington Group Bhd is an established ultra-high purity (UHP) delivery system provider with 18 years of experience. The next wave of growth will likely see the group leveraging its past experience, moving upstream and expanding into the supply and trading of industrial gases. Kelington has an advantage entering into this new business, which should also help to provide longer-term earnings visibility and better margins.
Kelington Group Bhd (+ve) TRADING of shares in Kelington Group Bhd (fundamental: 2.1/3, valuation: 1.1/3) triggered our momentum algorithm yesterday for the first time this month. Kelington closed up 15 sen or 14.42% at RM1.19, with 17.6 million shares traded, versus the counter’s 200-day average volume of 1.16 million shares. The group’s market capitalisation stood at RM300.99 million.
KUALA LUMPUR: Shares of little-known Kelington Group Bhd spiked 14.4% to close at an all-time high of RM1.19 yesterday on anticipation the US-China trade dispute would benefit the China-centric integrated engineering solutions provider which derives nearly half of its revenue from China.
KUALA LUMPUR (Sept 7): RHB Retail Research said Kelington Group Bhd may trend higher after it formed a white candle and breached above the 90 sen threshold.
KUALA LUMPUR: Integrated engineering solution provider Kelington Group Bhd, which expects to secure two more ultra high purity (UHP) projects by the end of this year, is training its eyes on opportunities in the UHP space that will emerge for the group as tensions between the two biggest economies in the world heighten.
KUALA LUMPUR: Gas Malaysia Bhd , Kelington Group Bhd , Zecon Bhd , IJM Corp Bhd and ECS ICT Bhd are among the stocks to watch on Thursday, according to JF Apex Research.
5209 5162 0151
KUALA LUMPUR (Aug 8): Based on corporate announcements and news flow today, stocks in focus tomorrow may include the following: Gas Malaysia Bhd, Axis REIT, Perak Corp Bhd, Kelington Group Bhd, Zecon Bhd, IJM Corp Bhd, ECS ICT Bhd, DKSH Holdings (Malaysia) Bhd, MRCB-Quill REIT and AirAsia Group Bhd.
DKSHY FLY 5209 5162 0151 5123 DKSHF 5908
There are many others that are unable to meet their obligations and they were all previously under Ministry of Finance Inc (MoF). Towards this end, the government has now placed many of the funds under the Energy, Science, Technology, Environment and Climate Change Ministry, led by Yeo Bee Yin(pic).
0025 0173 0151
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...